Clinical and genetic determinants of torsade de pointes risk - Wikidata - awgldk - TriplyDB

Clinical and genetic determinants of torsade de pointes risk

Clinical and genetic determinants of torsade de pointes risk

http://www.wikidata.org/entity/Q27014821

about

Human-induced pluripotent stem cell models of inherited cardiomyopathies Cardiovascular considerations in antidepressant therapy: an evidence-based review Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes Comprehensive analyses of ventricular myocyte models identify targets exhibiting favorable rate dependence Pharmacological treatment of acquired QT prolongation and torsades de pointes.Multifactorial QT Interval Prolongation and Takotsubo Cardiomyopathy.Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.Personalized medicine and atrial fibrillation: will it ever happen?Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil Clinical use of antidepressant therapy and associated cardiovascular risk Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes Prevalence and Risk Factors of Drug-Associated Corrected QT Prolongation in Elderly Hospitalized Patients: Results of a Retrospective Analysis of Data Obtained Over 6 Months.Psychotropic Drugs and Prolonged QTc Interval: Does it Really that Matter?Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.Interleukin-1β gene variants are associated with QTc interval prolongation following cardiac surgery: a prospective observational study.Predicting drug-induced QT prolongation and torsades de pointes: a review of preclinical endpoint measures.Long QT syndrome: beyond the causal mutation.Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.Depression requiring anti-depressant drug therapy in adult congenital heart disease: prevalence, risk factors, and prognostic value.Human induced pluripotent stem cell-derived versus adult cardiomyocytes: an in silico electrophysiological study on effects of ionic current block.Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study.Use of QT-prolonging medications in US emergency departments, 1995-2009.Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation Necessity to evaluate PI3K/Akt signalling pathway in proarrhythmia.The etomidate analog ET-26 HCl retains superior myocardial performance: Comparisons with etomidate in vivo and in vitro.Corrected QT interval prolongation during anesthetic induction for laryngeal mask airway insertion with or without cisatracurium.Rat engineered heart tissue: a novel tool in the safety pharmacology toolkit?Evaluating cardiac risk: exposure response analysis in early clinical drug development.Hypokalemia in women and methadone therapy are the strongest non-cardiologic factors associated with QT prolongation in an emergency department setting.EHRA/HRS/APHRS expert consensus on ventricular arrhythmias EHRA/HRS/APHRS expert consensus on ventricular arrhythmias Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities

P2860

Q26852052-2CD130A4-414D-4447-B5C8-6D55934687CB Q27021843-9F23D88E-5603-4115-9311-8451989A4F7A Q27030767-C02DED9B-9188-4FB0-B9E3-209AFE00C77D Q28541597-ADCBC4EB-C567-44DD-B3B0-39771659881E Q33166019-D063E665-B6BD-42A5-8FBF-0A62878FF937 Q33563312-6E29B46F-D103-4EBC-906C-4BAF718B0062 Q33695220-9350E4EF-6480-42F6-AA0B-A8550ED551EF Q34501117-E6D3340A-EDE6-45E8-B883-D3D445E49817 Q36085758-85D019B0-EBE5-4EE1-AC10-73B3CFBFFB9B Q36184863-B01F259B-A5E4-461C-B5EC-3920382BCC82 Q36365384-1F895051-7D9D-486E-A282-604AD679E363 Q36391603-815C8E48-9045-41FA-97B7-82E03CD5E372 Q36764542-9A05010E-9AEA-46A9-8839-BEA9A400C783 Q36970774-B9575EDD-4FAB-477D-965F-3F62F99A921B Q37306897-C903EBBE-79AD-432E-AF8E-3B09F8E4033C Q38112652-52D59CA7-9EB4-4EA2-90B1-7C283BA5726F Q38113488-E8D3AC0D-A943-4E4B-A117-6FAEEC987A49 Q39017656-F89E84D8-513A-4DBE-9623-F9F7CF03468E Q39147393-00DA4C84-5016-44AA-8ED1-16F6050E5E89 Q40599522-F862B953-A9CE-49A0-93B5-B90AEF7BADC5 Q42606979-C4CFAE16-1BF5-46CF-B26F-2990FF9AA105 Q43901924-C1FF2406-36DA-4766-8857-8E7904C36138 Q46041143-775CD140-B530-44CE-954A-16ABB14DA489 Q46933817-CD462D20-B19D-41D8-AB99-83816DA6D6C6 Q47127928-C6466CA2-7C16-4B8B-8C0A-6B94F6937F75 Q48258958-90A3D539-74E4-47A5-BB78-312D191C2A8F Q52628141-0730EDB9-CD1F-4A17-A6DB-8D5FF24B620C Q53450193-6CDD6E44-41FB-4B5B-9FDC-17863A04F152 Q55035299-11749953-3138-467D-8DBA-6225D6EA433A Q55546612-67454B24-F270-40AB-A503-CC2EF29402C8 Q57626635-25CACAFB-6785-4F32-9769-4408B5736727 Q57626770-425FB771-81CF-4B3E-8011-57AC6C16B81B Q58553697-7A6CE98D-9213-43CB-9C81-B9B4DF90AAAD

P2860

Clinical and genetic determinants of torsade de pointes risk

http://www.wikidata.org/entity/Q27014821

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Clinical and genetic determinants of torsade de pointes risk

@ast

Clinical and genetic determinants of torsade de pointes risk

@en

Clinical and genetic determinants of torsade de pointes risk

@nl

type

label

Clinical and genetic determinants of torsade de pointes risk

@ast

Clinical and genetic determinants of torsade de pointes risk

@en

Clinical and genetic determinants of torsade de pointes risk

@nl

prefLabel

Clinical and genetic determinants of torsade de pointes risk

@ast

Clinical and genetic determinants of torsade de pointes risk

@en

Clinical and genetic determinants of torsade de pointes risk

@nl

P1433

Q27014821-271B5A0D-C5D2-4E0F-B98C-DD59978D62FD

P1476

Q27014821-5F36F9C6-FD3D-4A2F-9355-4707B1FABE4E

P2093

Q27014821-02D20B03-12A7-41F4-BA59-1762D009A357

Q27014821-A355E451-5EE1-4A9C-809B-ABA4AE7F27F1

P2860

Q27014821-016824BC-3E4D-49A9-ACA2-46906226774B

Q27014821-045A5539-71A8-4BCF-A102-A1B4A2B081CB

Q27014821-049D5765-E74D-493A-AB0C-D5E1F10EE066

Q27014821-04B64DD2-662A-45F2-83F7-63AB0B85E528

Q27014821-06B0464A-C88D-46DC-8D5B-BA6AC80A40FB

Q27014821-084CCE39-F53A-49CA-BD53-4BE01F1BCC39

Q27014821-0851964D-FBFD-41B6-AE3D-F002C4CF4C57

Q27014821-0C87D1BF-65D8-4BB7-9A3D-07967AEBB4F0

Q27014821-0FD2DB43-A165-4228-962D-B79A403509B2

Q27014821-15294A5E-3A8B-4150-B27D-8FF445C135EB

P304

Q27014821-08993C18-7F43-43D6-A883-D32BA8562EE5

P31

Q27014821-A9FCBCF7-6386-48E2-A3BF-6528F37DE536

P356

Q27014821-3003B7E3-3607-4DD2-9BCD-5DBBB76060E8

P407

Q27014821-37573979-4028-498E-9759-1512FF7C2139

P433

Q27014821-9FE901EE-E5C3-4384-834F-7DAFB19061EC

P478

Q27014821-5710C149-266D-42BF-A239-EB2F5F942C48

P577

Q27014821-BF64FADC-0EED-4916-AF48-3D1390EDC2A5

P698

Q27014821-60CBC772-C29D-4DB7-B345-7CA9050668BA

P932

Q27014821-FDAFB25C-2FEC-460C-9789-15843D8CDB9D

P356

CIRCULATIONAHA.111.080887

P1433

P1476

Clinical and genetic determinants of torsade de pointes risk

@en

P2093

A. J. Sauer

http://www.w3.org/2001/XMLSchema#string

C. Newton-Cheh

http://www.w3.org/2001/XMLSchema#string

P2860

Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the old order Amish

Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development

Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2

Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability

A sodium-channel mutation causes isolated cardiac conduction disease

Increased mortality after dronedarone therapy for severe heart failure

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia

Modelling the long QT syndrome with induced pluripotent stem cells

P304

1684-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.111.080887

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22474311

http://www.w3.org/2001/XMLSchema#string

P932

3347483

http://www.w3.org/2001/XMLSchema#string